SA
WST icon

SRN Advisors’s West Pharmaceutical WST Stock Holding History

SRN Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,323
Closed -$1.25M – 115
2023
Q3 		$1.25M Buy
3,323
+64
+2% +$24.8K 1.24% 28
2023
Q2 		$1.25M Sell
3,259
-98
-3% -$35K 1.11% 35
2023
Q1 		$1.14M Buy
3,357
+579
+21% +$169K 1.05% 43
2022
Q4 		$654K Buy
2,778
+360
+15% +$85.3K 0.65% 79
2022
Q3 		$595K Sell
2,418
-513
-18% -$156K 0.5% 95
2022
Q2 		$886K Sell
2,931
-482
-14% -$157K 0.62% 73
2022
Q1 		$1.4M Buy
3,413
+32
+0.9% +$12.5K 0.62% 54
2021
Q4 		$1.59M Buy
3,381
+250
+8% +$108K 0.57% 48
2021
Q3 		$1.33M Sell
3,131
-2,312
-42% -$975K 0.62% 43
2021
Q2 		$1.95M Sell
5,443
-330
-6% -$109K 0.67% 50
2021
Q1 		$1.63M Sell
5,773
-1,107
-16% -$317K 0.58% 62
2020
Q4 		$1.93M Buy
+6,880
New +$1.93M 0.95% 47

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

SRN Advisors's WST Position: Q4 2023 in Review

SRN Advisors sold out of West Pharmaceutical (WST) in Q4 2023, closing a stake of 3,323 shares — an estimated $1.25M sold.

SRN Advisors first reported a position in WST in Q4 2020 and held it in 12 quarters. The position peaked at $1.95M in Q2 2021. 783 funds tracked by Wall St. Rank hold WST as of Q4 2023.

  • SRN Advisors reported no remaining West Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • SRN Advisors sold 3,323 West Pharmaceutical shares in Q4 2023, an estimated $1.25M.
  • SRN Advisors first reported a position in West Pharmaceutical in Q4 2020 and held it in 12 quarters.
  • SRN Advisors's West Pharmaceutical position peaked at $1.95M in Q2 2021.
  • 783 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2023.

Based on SRN Advisors's 13F filing for Q4 2023, filed 14 Jun 2024.